Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation 2006;114:84–231. 5. Bodnar E. The Medtronic Parallel (TM) valve and the lessons learned. J Heart Valve Dis 1996;5:572–573. 6. Van Nooten GJ, Van Belleghem Y, Caes F, François K, Van Overbeke H, Bové T, Taeymans...

conclusions high risk patients needing avr are optimal candidates for transcatheter aortic valve implantation. tavi is a valuable solution for high risk patients needing avr. obtained results are comparable to results in transthoracic avr in standard candidates for aortic valve implantation. background transcatheter aortic valve implantation (tavi) has emerged as an alternative treatment to cla...

INTRODUCTION Pulmonary valve replacement (PVR) is being performed more commonly late after the correction of tetralogy of Fallot. Most valves are replaced with an allograft or xenograft, although reoperations are a common theme. Mechanical prostheses have a less favorable reputation due to the necessity of lifelong anticoagulation therapy and higher risk of thrombosis, but they are also less li...

conclusions preservation of mitral annulus and papillary muscle continuity may enhance post- mvr cardiac performance with low mortality and morbidity rates. the risk of pvd was not significantly higher than conventional mvr in our series. results the improvement of functional status was seen in almost all survivors but was more obvious in the group i. in early follow-up, 56.4% of group i cases ...

As a result of the durability problems associated with the first Abrams-Lucas mitral valve, a redesigned model has recently been introduced into limited clinical trials. The new valve was subjected to in-vitro pulsatile flow studies, and measurements were made of mean diastolic pressure gradient and volume of reflux on closure. Similar measurements were made on other mitral valve prostheses of ...

transcatheter aortic valve implantation (tavi) is a new therapeutic option for patients with severe aortic stenosis with unacceptable surgical risk for conventional aortic valve surgery. a bicuspid aortic valve (bav) is the most common congenital cardiac disorder (1% of the population) and currently is considered exclusion criteria for tavi, because it predicts an increased risk of adverse aort...

Currently-used mechanical and biological heart valve prostheses have several disadvantages. Mechanical prostheses, based on carbon, metallic and polymeric components, require permanent anticoagulation treatment, and their usage often leads to adverse reactions, e.g. thromboembolic complications and endocarditis. Xenogenous and allogenous biological prostheses are associated with immune reaction...

Background—Leaflet escape is a mode of structural valve failure for mechanical prostheses. This complication previously has been reported for both monoleaflet and bileaflet valve models. We report 2 leaflet escape occurrences observed in 2 patients who underwent valve replacement with a TRI Technologies valve prosthesis. Methods and Results—At the University of Padua, between November 2000 and ...

BACKGROUND Leaflet escape is a mode of structural valve failure for mechanical prostheses. This complication previously has been reported for both monoleaflet and bileaflet valve models. We report 2 leaflet escape occurrences observed in 2 patients who underwent valve replacement with a TRI Technologies valve prosthesis. METHODS AND RESULTS At the University of Padua, between November 2000 an...